ADVERTISEMENT

India, Japan sign pact on stem cell research

September 13, 2017 10:31 pm | Updated 10:33 pm IST - NEW DELHI

Prime Minister Narendra Modi accompanies Japan Prime Minister Shinzo Abe and his wife Akie Abe during their visit to the Sabarmati Ashram, in Ahmedabad, Gujarat on Wednesday. Vijay Soneji

In the light of Japan’s Prime Minister Shinzo Abe’s visit to India, the two countries have signed a host of agreements on Wednesday to further cooperation in science and technology, including research into stem-cells for making bone-marrow transplants more accessible.

The Department of Biotechnology (DBT) already has an India-Japan cooperative programme that has Christian Medical College & Hospital, Vellore, and Kyoto University, Japan, as participants.

Though the DBT and Japan’s National Institute of Advanced Industrial Science and Technology (AIST) have been collaborating in these areas, they renewed the agreement for five more years on Wednesday.

ADVERTISEMENT

“The aim of the programme is to develop infrastructure and expertise for India to be a competitive force in regenerative medicine and induced pluripotent stem cell biology. The focus of the collaboration is on developing treatments for sickle-cell anaemia, Beta thalassemia and brain disorders, and creating a haplobank relevant to Indian populations,” said a press release. A haplobank refers to a specially maintained collection of embryonic cells that can, in theory, be directed to become any kind of cell and thus progenitor of replacement organs.

Japanese scientist Shinya Yamanaka was a co-recipient of the Nobel Prize for medicine for discovering ways to reprogram mature stem cells.

“Through this programme, Indian scientists will be part of a global network that shares research into and knowledge of these aspects of stem cell technology,” said K. VijayRaghavan, Secretary, DBT. “An immediate focus would be on using this to help in bone-marrow cells and transplants by identifying the genetic variants of such cells in Indian populations.”

ADVERTISEMENT

This is a Premium article available exclusively to our subscribers. To read 250+ such premium articles every month
You have exhausted your free article limit.
Please support quality journalism.
You have exhausted your free article limit.
Please support quality journalism.
The Hindu operates by its editorial values to provide you quality journalism.
This is your last free article.

ADVERTISEMENT

ADVERTISEMENT